ALC vs TXG
Alcon Inc vs 10x Genomics, Inc. — AI-powered side-by-side comparison
VS
TXG
10x Genomics, Inc.
53
Watch
| Metric | ALC | TXG |
|---|
| AI Score |
68
|
53
|
| Price |
$75.39
|
$58.48
|
| P/E Ratio |
45.39×
|
-99.12×
|
| ROE |
4.4%
|
-5.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
70.0%
|
| Debt / Equity |
0.24×
|
0.10×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
79.3
|
| Beta |
0.703
|
2.039
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus TXG.
ALC leads by 15 points.
ALC scores 68/100 (Buy) versus TXG at 53/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
TXG Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical